Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events.
Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events.
复制标题
DOI：
10.1158/1078-0432.ccr-18-0236
复制
发表时间：
2018-08-15
期刊：
影响因子：
--
通讯作者：
Jain RK
中科院分区：
文献类型：
--
作者：
Pinter M;Kwanten WJ;Jain RK
治疗相关的副作用是癌症治疗中的一个主要临床问题。它们导致治疗依从性降低以及发病率和死亡率增加。众所周知的是化疗对心脏的后遗症，特别是在儿童癌症幸存者身上。因此，减轻癌症治疗的不良事件的措施可能会在短期和长期内改善癌症患者的健康和生活质量。肾素血管紧张素系统(RAS)影响癌症的所有特征，阻断RAS与几种癌症类型的预后改善有关。也有越来越多的证据表明，抑制RAS可能能够减轻甚至预防某些类型的癌症治疗相关的不良反应。在这篇综述中，我们总结了RAS抑制剂在减轻癌症治疗相关不良事件方面的潜力，特别强调了化疗引起的心脏毒性、辐射损伤和动脉高压。
Treatment-related side effects are a major clinical problem in cancer treatment. They lead to reduced compliance to therapy as well as increased morbidity and mortality. Well-known are the sequelae of chemotherapy on the heart, especially in childhood cancer survivors. Therefore, measures to mitigate the adverse events of cancer therapy may improve health and quality of life in cancer patients, both in short and long term. The renin angiotensin system (RAS) affects all hallmarks of cancer, and blockage of the RAS is associated with an improved outcome in several cancer types. There is also increasing evidence that inhibition of the RAS might be able to alleviate or even prevent certain types of cancer treatment related adverse effects. In this review, we summarize the potential of RAS inhibitors to mitigate cancer treatment related adverse events, with a special emphasis on chemotherapy-induced cardiotoxicity, radiation injury, and arterial hypertension.